AVArja Viinanen

Arja Viinanen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arja Viinanen has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Asthma Severity and Exacerbation Frequency on Burden of Disease Related Costs in Finland

    by Mariann Lassenius, Juhani Aakko, Sara Hallberg, Mary Dillon, Kaisa Nieminen, Hannu Kankaanranta, Arja Viinanen, Paula Kauppi, Lauri Lehtimäki

    Purpose: Evaluating productivity loss and healthcare costs among working-aged individuals with asthma is critical for comprehending the economic burden and guiding healthcare policy decisions. An optimized care of asthma could result in substantial societal benefits by improving workforce participation and reducing healthcare resource use. Recent data on the impact of both asthma severity and exacerbation frequency on overall costs are scarce. Patients and Methods: In this retrospective study from Finland, 89,606 working aged patients with asthma were followed from national registers for four years from 2017 to 2020 with the objective to assess the impact of asthma severity and exacerbation frequency on the overall costs arising from direct healthcare resource utilization (visits and drug purchases) and productivity loss (long term sick leaves and disability pensions) with gamma regression models. Results: Severe asthma, noted in 10% of patients, increased healthcare resource utilization and productivity loss costs by 30% and frequent exacerbations, noted in 13% of patients, by 25%, independently of each other and of age, sex and Charlson comorbidity index. The annual overall cost per patient was € 14,359 for severe asthma with frequent exacerbations, followed by € 11,802 in those with non-severe asthma and frequent exacerbations. Most costs were related to productivity losses (60%) compared to direct healthcare costs (40%). The prevalence of asthma increased from 2.7% to 3.0% over the four-year period, an increase was also observed in the subgroup of those with severe asthma. Conclusion: A substantial disease burden associated with frequent exacerbations in both patients with asthma and severe asthma leads to increased productivity loss and direct healthcare costs. The estimated the total annual cost of working-aged patients with asthma was € 715 million in Finland, with 25% of additional costs associated with frequent exacerbations, indicating the potential savings that could be achievable through improved disease control. Plain Language Summary: Why was the study done? The study aimed to understand the economic burden of asthma in relation to disease severity and exacerbation frequency among working-aged individuals in Finland. What did the researchers find? The total annual cost of asthma for working-age patients in Finland was estimated at € 715 million. Patients with severe asthma had 30% higher annual healthcare and productivity loss costs, compared to those with non-severe asthma. Frequent exacerbations also increased annual costs by 25%, irrespective of asthma severity. The annual cost per patient was highest for those with severe asthma and frequent exacerbations (€ 14,359), followed by those with non-severe asthma and frequent exacerbations (€ 11,802). Most costs (60%) were related to productivity losses, with direct healthcare costs making up the remaining 40%. What do the results mean? The study highlights that the significant economic burden of asthma is driven by exacerbation frequency, suggesting that better disease control could lead to significant savings and enhance workforce participation.


  • Open Access

    Clinical functioning information tool – coronavirus disease 2019 (ClinFIT COVID-19): psychometric evaluation and development of an interval-scaled functioning score across the care continuum

    by Masahiko Mukaino, Catarina Aguiar Branco, Alia Alghwiri, Sonia Amato, Antonios Kontaxakis, Mihai Berteanu, Hüma Bölük Şenlikci, Pinar Borman, Salmane Diouane, Maryam Fourtassi, et al.

    Objective: to report on the development and global testing of the COVID-19 version of the International Classification of Functioning, Disability and Health-based Clinical Functioning Information Tool called “ClinFIT COVID-19” to collect functioning data of rehabilitation patients across the care continuum to establish an interval-scaled functioning score. Design: Multicentre, cross-sectional observational study. Subjects/Patients: Rehabilitation patients in acute, post-acute, and long-term settings. Methods: Three context-specific versions (13–16 ICF categories) of ClinFIT-COVID-19 were administered to collect information on patient functioning. Rasch analysis examined psychometric properties and generated conversion tables from ordinal raw scores to a 0–100 interval metric. Results: Twenty-six study centres in 17 countries across the globe collected data from 1,747 patients. Problems in exercise tolerance functions were most frequently reported in the acute and post-acute settings (74.2%; 87.6%), while long-term care patients most frequently reported pain as problematic (71.1%). With a testlets approach and item splitting, all 3 ClinFIT COVID-19 versions satisfied Rasch model expectations (item-trait χ² p > 0.05; PSI 0.742–0.812), making it feasible to develop respective transformation tables. Conclusion: This study found the psychometric properties of ClinFIT COVID-19 acceptable. Future studies are needed to validate the use of the transformation tables to monitor functioning and evaluate intervention impact.


  • Open Access

    Factors associated with the development of severe asthma

    by Arja Viinanen, Pinja Ilmarinen, Juha Mehtälä, Juulia Jylhävä, Tero Ylisaukko-Oja, Juhana J. Idänpään-Heikkilä, Hannu Kankaanranta, Lauri Lehtimäki


  • Comorbidities and mortality in relation to asthma severity and exacerbations.

    by Arja Viinanen, Anton Klåvus, Helga Olsen, Annina Lyly, Mariann I Lassenius, Hannu Kankaanranta, Lauri Lehtimäki

    Background: Severe asthma patients have a significant disease burden, however, comorbidities and mortality by disease severity are not fully known. Aims and objectives: Explore comorbidity and mortality in bionaïve asthmatics by severity and exacerbations. Methods: Observational, registry-based, cohort study in all Finnish patients with physician-diagnosed asthma and a collection of obstructive airways drugs from Jan 2015 – Dec 2016 (followed until Dec 2020). Severe asthma was defined by treatment intensity (fluticasone propionate ≥ 800 μg/day + 2nd controller). Frequent exacerbations were defined as either two emergency visits/one hospitalization or baseline prednisolone >600 mg/year. Four cohorts were created based on severity (severe vs non-severe) and exacerbations (frequent vs non-frequent), matched on age, sex and district (n=5125/cohort). Results and conclusions: Cardiovascular and respiratory comorbidities were more common in asthmatics with frequent exacerbations, independent of severity. In patients with frequent exacerbations at baseline, cumulative no. of exacerbations was higher in severe vs. non-severe disease (mean 5.14 vs. 0.86 at 48 months). Compared to non-severe asthma with infrequent exacerbations, patients with severe asthma and frequent exacerbations had higher respiratory-, cardiovascular- and overall mortality (rate ratio 1.93, 8.17 and 1.9, respectively, p<0.001). Patients with severe asthma and frequent exacerbations have significant comorbidity and increased mortality. There is a need for effective therapies to reduce exacerbations in bionaïve patients uncontrolled by high intensity treatment. Impact of better treatment on comorbidities/mortality needs to be elucidated.

  • Open Access

    Healthcare Resource Utilisation of Severe Uncontrolled T2low and Non-T2low Asthma in Finland During 2018-2021

    by Josefine Persson, Juhani Aakko, Saara Kaijala, Mariann Lassenius, Arja Viinanen, Hannu Kankaanranta, Lauri Lehtimäki

    Purpose: Patients with asthma and low levels of type 2 inflammatory biomarkers (T2 low) have limited effective treatment options. Such biomarkers include eg blood eosinophils (b-eos) and fractional exhaled nitric oxide (FeNO). The healthcare resource utilisation (HCRU) of severe uncontrolled T2 low asthma remains unexplored. Thus, this study aimed to estimate the HCRU of T2 low and non-T2 low severe uncontrolled asthma patients using real-world data in Finland. Patients and Methods: Adult patients with an asthma diagnosis during baseline (2012– 2017) at the pulmonary department of Turku University Hospital were included and followed during 2018– 2021, or until death. Total HCRU costs and respiratory-related HCRU costs were evaluated. The main drivers for the HCRU and costs were assessed with gamma and negative binomial regression models. Results: Of the severe uncontrolled asthma patients with T2 status available, 40% (N=66) were identified with T2 low and 60% (N=103) with non-T2 low asthma. The average cumulative cost per patient was similar in patients with T2 low compared with non-T2 low, with all-cause costs cumulating in four years of follow-up to 37,524€ (95% CI: 27,160, 47,888) in T2 low compared to 34,712€ (25,484, 43,940) in non-T2 low. The corresponding average cumulative respiratory-related costs were 5178€ (3150, 7205) in T2 low compared to 5209€ (4104, 6313) in non-T2 low. Regression modelling identified no differences between the T2-status groups when assessing all-cause healthcare costs per patient-year (PPY). On the other hand, the regression modelling predicted more inpatient days PPY for severe uncontrolled patients with T2 low status compared to the patients with non-T2 low status. Conclusion: Patients with uncontrolled severe T2 low asthma use equal healthcare resources as corresponding non-T2 low patients. This study brought new insights into the HCRU of severe uncontrolled asthma patients per T2 status, which has not previously been investigated.


  • The prevalence of severe asthma and severe eosinophilic asthma in Finland

    by Arja Viinanen, Pinja Ilmarinen, Juha Mehtälä, Tero Ylisaukko-Oja, Juhana J Idänpään-Heikkilä, Hannu Kankaanranta, Lauri Lehtimäki

    Background: Phenotype and severity of asthma influence treatment choice, asthma control, and quality of life. Therefore, it is essential to understand the prevalence of various subgroups. Aims: To assess the prevalence of asthma, severe asthma, and severe eosinophilic asthma among Finnish adults. Methods: All Finnish adults who had asthma diagnosis either in the secondary (ICD-10: J45) or primary care (ICD-10: J45 or ICPC-2: R96) during 2014–2019 were included in the study. Asthma was categorized as severe based on dispensed ICS and OCS doses, hospitalizations, and use of biological treatments. Eosinophilic asthma was assessed among those with severe asthma and at least one blood eosinophil count (bEos) available. Severe asthma was regarded as eosinophilic when bEos was ≥0.3x109/l at least once, non-eosinophilic when all bEos values were 9/l (at least 3 counts available) and difficult-to-classify if 1-2 bEos values were available and were 9/l. Results: The study population included 278,172 adult patients with a primary or secondary care asthma diagnosis corresponding to a population prevalence of 6%. Altogether, 137,772 individuals (50% of the study population) had asthma diagnosis in secondary care and 12,679 (9%) of these patients had severe asthma. Data on bEos count was available for 4,178 patients with severe asthma. A total of 2,256 (54%) of these patients were classified as eosinophilic, 837 (20%) as non-eosinophilic, and 1,085 (26%) as difficult to classify. Conclusions: The prevalence of asthma was estimated to be 6% in the adult Finnish population. Among the secondary care asthma patients, 9% had severe asthma and 54% of them had eosinophilic severe asthma. Funded by GSK (ID219294).


  • Open Access

    Severe asthma trajectories in adults: findings from the NORDSTAR cohort

    by Anna von Bülow, Susanne Hansen, Patrik Sandin, Olivia Ernstsson, Christer Janson, Lauri Lehtimäki, Hannu Kankaanranta, Charlotte Ulrik, Bernt Bøgvald Aarli, Kirk Geale, et al.

    Background: There is limited evidence on the pathways leading to severe asthma and we are presently unable to effectively predict the progression of the disease. We aimed to describe the longitudinal trajectories leading to severe asthma and to describe clinical events preceding disease progression in a nationwide population of patients with severe asthma.Methods: We conducted an observational study based on Swedish data from the NORdic Dataset for aSThmA Research (NORDSTAR) research collaboration platform. We identified adult patients with severe asthma in 2018 according to the European Respiratory Society/American Thoracic Society definition and used latent class analysis to identify trajectories of asthma severity over a 10-year retrospective period from 2018.Results: Among 169 128 asthma patients, we identified 4543 severe asthma patients. We identified four trajectories of severe asthma that were labelled as: trajectory 1 “consistently severe asthma” (n=389 (8.6%)), trajectory 2 “gradual onset severe asthma” (n=942 (20.7%)), trajectory 3 “intermittent severe asthma” (n=1685 (37.1%)) and trajectory 4 “sudden onset severe asthma” (n=1527 (33.6%)). “Consistently severe asthma” had a higher daily inhaled corticosteroid dose and more prevalent osteoporosis compared with the other trajectories. Patients with “gradual onset severe asthma” and “sudden onset severe asthma” developed type 2-related comorbidities concomitantly with development of severe asthma. In the latter group, this primarily occurred within 1–3 years preceding onset of severe asthma.Conclusions: Four distinct trajectories of severe asthma were identified illustrating different patterns of progression of asthma severity. This may eventually enable the development of better preventive management strategies in severe asthma.


  • Open Access

    Type 2 Low Biomarker Stability and Exacerbations in Severe Uncontrolled Asthma

    by Arja Viinanen, Juhani Aakko, Mariann I. Lassenius, Gunilla Telg, Kaisa Nieminen, Saara Kaijala, Lauri Lehtimäki, Hannu Kankaanranta

    We investigated the stability of T2 low status, based on low levels of T2 biomarkers, and exacerbation rates in T2 low and non-T2 low asthma from clinical retrospective data of severe uncontrolled asthma patients. Knowledge of the T2 low biomarker profile is sparse and biomarker stability is uncharted. Secondary care patients with severe uncontrolled asthma and at least two blood eosinophil counts (BEC) and fractional exhaled nitric oxide (FeNO) measured for determination of type 2 inflammation status were evaluated from a follow-up period of 4 years. Patients were stratified into four groups: T2 low150 (n = 31; BEC < 150 cells/µL and FeNO < 25 ppb), non-T2 low150 (n = 138; BEC > 150 cells/µL and/or FeNO > 25 ppb), T2 low300 (n = 66; BEC < 300 cells/µL and FeNO < 25 ppb), and non-T2 low300 (n = 103; BEC > 300 cells/µL and/or FeNO > 25 ppb). Exacerbation rates requiring hospital care, stability of biomarker status, and cumulative OCS and ICS doses were assessed during follow-up. Among patients with severe uncontrolled asthma, 18% (n = 31) were identified as T2 low150, and 39% (n = 66) as T2 low300. In these groups, the low biomarker profile was stable in 55% (n = 11) and 72% (n = 33) of patients with follow-up measures. Exacerbation rates were different between the T2 low and non-T2 low groups: 19.7 [95% CI: 4.3–45.6] in T2 low150 vs. 8.4 [4.7–13.0] in non-T2 low150 per 100 patient-years. BEC and FeNO are useful biomarkers in identifying T2 low severe uncontrolled asthma, showing a stable follow-up biomarker profile in up to 72% of patients. Repeated monitoring of these biomarkers is essential in identifying and treating patients with T2 low asthma.


  • Open Access

    Prevalence and management of severe asthma in the Nordic countries: findings from the NORDSTAR cohort

    by Susanne Hansen, Anna von Bülow, Patrik Sandin, Olivia Ernstsson, Christer Janson, Lauri Lehtimäki, Hannu Kankaanranta, Charlotte Ulrik, Bernt Bøgvald Aarli, Hanna Fues Wahl, et al.

    Background: Real-life evidence on prevalence and management of severe asthma is limited. Nationwide population registries across the Nordic countries provide unique opportunities to describe prevalence and management patterns of severe asthma at population level. In nationwide register data from Sweden, Norway and Finland, we examined the prevalence of severe asthma and the proportion of severe asthma patients being managed in specialist care.Methods: This is a cross-sectional study based on the Nordic Dataset for Asthma Research (NORDSTAR) research collaboration platform. We identified patients with severe asthma in adults (aged ≥18 years) and in children (aged 6–17 years) in 2018 according to the European Respiratory Society/American Thoracic Society definition. Patients managed in specialist care were those with an asthma-related specialist outpatient contact (only available in Sweden and Finland).Results: Overall, we identified 598 242 patients with current asthma in Sweden, Norway and Finland in 2018. Among those, the prevalence of severe asthma was 3.5%, 5.4% and 5.2% in adults and 0.4%, 1.0%, and 0.3% in children in Sweden, Norway and Finland, respectively. In Sweden and Finland, 37% and 40% of adult patients with severe asthma and two or more exacerbations, respectively, were managed in specialist care; in children the numbers were 56% and 41%, respectively.Conclusion: In three Nordic countries, population-based nationwide data demonstrated similar prevalence of severe asthma. In children, severe asthma was a rare condition. Notably, a large proportion of patients with severe asthma were not managed by a respiratory specialist, suggesting the need for increased recognition of severe asthma in primary care.


  • NORDSTAR: paving the way for a new era in asthma research

    by Kirk Geale, Hatef Darabi, Maria Lindh, Hanna Fues Wahl, Oskar Ström, Hui Cao, Luisa Alvares, Rikke Dodge, Emil Loefroth, Alan Altraja, et al.